De effecten van kortdurend vasten rondom chemotherapie

Langdurige calorierestrictie zorgt bij proefdieren voor vermindering van het ontstaan van kanker1 en verminderde tumorprogressie en uitzaaiingen in muizen.2 Ook bij mensen leidt langdurige calorierestrictie tot verbetering van metabole en hormonale waarden die geassocieerd zijn met het risico op het krijgen van kanker.3 Langdurige calorierestrictie is echter niet goed mogelijk als klinische interventie in patiënten met kanker, gezien de lange duur van de interventie en onacceptabel gewichtsverlies. Kortdurend vasten, bijvoorbeeld 48 tot 96 uur, zorgt voor verbetering van de effectiviteit van verschillende antikankerbehandelingen in proefdieren met vele verschillende typen tumoren en kan tegelijkertijd de bijwerkingen van de therapie verminderen.4

Beste bezoeker, u heeft geen toegang.

Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.

U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!

Auteur

Stefanie de Groot

Trefwoorden:

Verschenen in

Referenties

  1. Dirx MJ, Zeegers MP, Dagnelie PC, et al. Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int. J. Cancer 106, 766-770 (2003).
  2. Lv M, Zhu X, Wang H, et al. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS. One 9, e115147 (2014).
  3. Ravussin E, et al. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. J. Gerontol. A Biol. Sci. Med. Sci 70, 1097-1104 (2015).
  4. Lee C, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med 4, 124ra127 (2012).
  5. Raffaghello L, Lee C, Safdie FM, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. U. S. A 105, 8215-8220 (2008).
  6. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene 30, 3305-3316 (2011).
  7. Safdie F, Brandhorst S, Wei M, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS. One 7, e44603 (2012).
  8. Di Biase S, Longo VD. Fasting-induced differential stress sensitization in cancer treatment. Mol Cell Oncol 3, e1117701 (2016).
  9. Michalsen A, Hoffmann B, Moebus S, et al. Incorporation of fasting therapy in an integrative medicine ward: evaluation of outcome, safety, and effects on lifestyle adherence in a large prospective cohort study. J. Altern. Complement Med 11, 601-607 (2005).
  10. Caccialanza R, Aprile G, Cereda E, et al. Fasting in oncology: a word of caution. Nat Rev Cancer (2019).
  11. Arends J, Baracos V, Bertz H, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr 36, 1187-1196 (2017).
  12. Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet 384, 755-765 (2014).
  13. Ferroni P, Riondino S, Laudisi A, et al. Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. Oncologist 21, 1041-1049 (2016).
  14. Duggan C, Wang CY, Neuhouser ML, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int. J Cancer 132, 1191-1200 (2013).
  15. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21, 433-440 (2003).
  16. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12, 159-169 (2012).
  17. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr. Rev 15, 80-101 (1994).
  18. Brandhorst S, Choi IY, Wei M, et al. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan. Cell Metab 22, 86-99 (2015).
  19. Safdie FM, Dorff T, Quinn D, et al. Fasting and cancer treatment in humans: A case series report. Aging (Albany. NY) 1, 988-1007 (2009).
  20. Bauersfeld SP, Kessler CS, Wischnewsky M, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer 18, 476 (2018).
  21. de Groot S, Vreeswijk MP, Welters MJ, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer 15, 652 (2015).
  22. de Groot S, Lugtenberg RT, Cohen D, et al. Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial. Nat Commun 11, 3083 (2020).
  23. Lugtenberg RT, de Groot S, Kaptein AA, et al. Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial. Breast Cancer Res Treat (2020).

Gerelateerde artikelen

Ginseng vermindert risico op kanker
Intermitterend vasten vermindert inflammatie bij overgewicht
Zoetstof met een bittere nasmaak?
Diabetes omkeerbaar: nieuwe omvangrijke studie
Hoge ALA-inname vermindert sterfterisico met 10%